Advanced

The Value of the UroVysion((R)) Assay for Surveillance of Non-Muscle-Invasive Bladder Cancer.

Gudjonsson, Sigurdur LU ; Isfoss, Björn; Hansson, Kerstin; Domanski, Anna-Maria; Warenholt, Janina; Soller, Wolfgang LU ; Lundberg, Lena-Maria LU ; Liedberg, Fredrik LU ; Grabe, Magnus LU and Månsson, Wiking LU (2008) In European Urology 54(2). p.402-408
Abstract
OBJECTIVE: Patients with non-muscle-invasive bladder cancer are traditionally followed by repeat cystoscopy and urine cytology. A fluorescence in situ hybridisation technique called UroVysion((R)) (UV) is now available for clinical diagnosis of urothelial cancer cells. The aim of the present study was to compare UV analysis with routine follow-up methods. METHODS: We studied an unselected cohort of patients undergoing cystoscopy follow-ups at two Swedish centres in 2004-2005. All patients were investigated by cystoscopy, cytology, and UV assay. The UV assay was evaluated with regards to sensitivity, specificity, and positive predictive value for tumour recurrence. RESULTS: In all, 159 cases were analysed. UV had a 30% overall sensitivity... (More)
OBJECTIVE: Patients with non-muscle-invasive bladder cancer are traditionally followed by repeat cystoscopy and urine cytology. A fluorescence in situ hybridisation technique called UroVysion((R)) (UV) is now available for clinical diagnosis of urothelial cancer cells. The aim of the present study was to compare UV analysis with routine follow-up methods. METHODS: We studied an unselected cohort of patients undergoing cystoscopy follow-ups at two Swedish centres in 2004-2005. All patients were investigated by cystoscopy, cytology, and UV assay. The UV assay was evaluated with regards to sensitivity, specificity, and positive predictive value for tumour recurrence. RESULTS: In all, 159 cases were analysed. UV had a 30% overall sensitivity for the 27 biopsy-proven recurrences and 70% sensitivity for high-risk tumours (pT1 and carcinoma in situ [CIS]). The specificity of UV was 95%. UV detected all six CIS cases in the study and was predictive in two additional patients who developed CIS within 1 yr of inclusion. Cytology was positive in four of those eight CIS cases and atypical in the other four. CONCLUSIONS: The UV assay cannot replace cystoscopy for surveillance of patients with non-muscle-invasive bladder cancer, but it may be valuable as a supplement to traditional measures for detecting CIS. Before any conclusions can be drawn regarding the efficacy of novel markers of bladder cancer, they must be studied in bladder cancer patients undergoing endoscopic surveillance. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bladder cancer, cystoscopy, cytology, FISH, follow-up, sensitivity, surveillance, specificity
in
European Urology
volume
54
issue
2
pages
402 - 408
publisher
Elsevier
external identifiers
  • wos:000258251300022
  • pmid:18082934
  • scopus:45849126870
ISSN
1873-7560
DOI
10.1016/j.eururo.2007.11.051
language
English
LU publication?
yes
id
5ef1c45f-c09b-4942-a10c-a1ccae6cbef7 (old id 1035210)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18082934?dopt=Abstract
date added to LUP
2008-04-01 11:50:34
date last changed
2017-02-22 11:44:20
@article{5ef1c45f-c09b-4942-a10c-a1ccae6cbef7,
  abstract     = {OBJECTIVE: Patients with non-muscle-invasive bladder cancer are traditionally followed by repeat cystoscopy and urine cytology. A fluorescence in situ hybridisation technique called UroVysion((R)) (UV) is now available for clinical diagnosis of urothelial cancer cells. The aim of the present study was to compare UV analysis with routine follow-up methods. METHODS: We studied an unselected cohort of patients undergoing cystoscopy follow-ups at two Swedish centres in 2004-2005. All patients were investigated by cystoscopy, cytology, and UV assay. The UV assay was evaluated with regards to sensitivity, specificity, and positive predictive value for tumour recurrence. RESULTS: In all, 159 cases were analysed. UV had a 30% overall sensitivity for the 27 biopsy-proven recurrences and 70% sensitivity for high-risk tumours (pT1 and carcinoma in situ [CIS]). The specificity of UV was 95%. UV detected all six CIS cases in the study and was predictive in two additional patients who developed CIS within 1 yr of inclusion. Cytology was positive in four of those eight CIS cases and atypical in the other four. CONCLUSIONS: The UV assay cannot replace cystoscopy for surveillance of patients with non-muscle-invasive bladder cancer, but it may be valuable as a supplement to traditional measures for detecting CIS. Before any conclusions can be drawn regarding the efficacy of novel markers of bladder cancer, they must be studied in bladder cancer patients undergoing endoscopic surveillance.},
  author       = {Gudjonsson, Sigurdur and Isfoss, Björn and Hansson, Kerstin and Domanski, Anna-Maria and Warenholt, Janina and Soller, Wolfgang and Lundberg, Lena-Maria and Liedberg, Fredrik and Grabe, Magnus and Månsson, Wiking},
  issn         = {1873-7560},
  keyword      = {bladder cancer,cystoscopy,cytology,FISH,follow-up,sensitivity,surveillance,specificity},
  language     = {eng},
  number       = {2},
  pages        = {402--408},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {The Value of the UroVysion((R)) Assay for Surveillance of Non-Muscle-Invasive Bladder Cancer.},
  url          = {http://dx.doi.org/10.1016/j.eururo.2007.11.051},
  volume       = {54},
  year         = {2008},
}